Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.980
+0.070 (2.41%)
Nov 18, 2026, 4:00 PM EST - Market closed
Galectin Therapeutics Market Cap
Galectin Therapeutics has a market cap or net worth of $300.61 million as of November 18, 2026. It is the 17,852nd most valuable company in the world and the 3,150th biggest in the United States. Its market cap has decreased by 22.28% in one year.
Market Cap
300.61M
Enterprise Value
327.76M
1-Year Change
-22.28%
Global Rank
Country Rank
#3,150 United States
Category
ChartMarket Cap Chart
Since September 10, 2003, Galectin Therapeutics's market cap has increased from $106.80M to $300.61M, an increase of 181.47%. That is a compound annual growth rate of 4.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 18, 2026 | 300.61M | 12.08% |
| Dec 31, 2025 | 268.20M | 231.11% |
| Dec 31, 2024 | 81.00M | -21.13% |
| Dec 29, 2023 | 102.70M | 52.83% |
| Dec 30, 2022 | 67.20M | -45.28% |
| Dec 31, 2021 | 122.80M | -3.99% |
| Dec 31, 2020 | 127.90M | -21.39% |
| Dec 31, 2019 | 162.70M | 15.31% |
| Dec 31, 2018 | 141.10M | 18.57% |
| Dec 29, 2017 | 119.00M | 313.19% |
| Dec 30, 2016 | 28.80M | -26.53% |
| Dec 31, 2015 | 39.20M | -48.96% |
| Dec 31, 2014 | 76.80M | -48.11% |
| Dec 31, 2013 | 148.00M | 352.60% |
| Dec 31, 2012 | 32.70M | -55.81% |
| Dec 30, 2011 | 74.00M | 32.14% |
| Dec 31, 2010 | 56.00M | 288.89% |
| Dec 31, 2009 | 14.40M | 234.88% |
| Dec 31, 2008 | 4.30M | -84.81% |
| Dec 31, 2007 | 28.30M | 111.19% |
| Dec 29, 2006 | 13.40M | -83.91% |
| Dec 30, 2005 | 83.30M | 21.96% |
| Dec 31, 2004 | 68.30M | -23.94% |
| Dec 31, 2003 | 89.80M | -15.92% |
| Sep 10, 2003 | 106.80M | - |
View and export this data all the way back to 2003. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Inovio Pharmaceuticals | 316.55M |
| ProKidney | 314.48M |
| Nautilus Biotechnology | 309.51M |
| Relmada Therapeutics | 304.61M |
| X4 Pharmaceuticals | 304.30M |
| Greenwich LifeSciences | 302.08M |
| Benitec Biopharma | 298.70M |
| Agenus | 289.58M |